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cause of morbidity and mortality in DMD patients. We hypothesized
that abnormal [Ca2+]i handling in DMD iPSC-CMs results in
depressed positive inotropic response to β-adrenergic stimulation.
DMD iPSC-CMs were generated from male and female patients.
Methods and results: To test the hypothesis, [Ca2+]i transients and
contractions were recorded from stimulated iPSC-CMs clusters using
fura-2 fluorescence and video edge detector, in the absence and
presence of the β-adrenergic agonist isoproterenol, which increases
SR Ca2+ release through PKA-regulated RyR2. The results demon-
strated concentration-dependent positive inotropic and lusitropic
effects in healthy iPSC-CMs, in both [Ca2+]i transient and con-
traction parameters. In contrast, compared to healthy iPSC-CMs, the
[Ca2+]i transient and contraction]i of the female and male DMD
iPSC-CMs displayed attenuated inotropic responses to isoproterenol.
To decipher the underlying mechanism, we determined SR Ca2+
release in DMD iPSC-CMs by means of a brief application of caffeine.
The caffeine-induced Ca2+ signal area of DMD iPSC-CMs (male
and female) and amplitude (female) were smaller than control. In
addition, Seahorse XF analyzer demonstrated decreased (compared
to control) oxidative phosphorylation accompanied by a correlated
increase in glycolysis in DMD iPSC-CMs. Accordingly, mass spec-
trometry analysis showed a dramatic fall in phosphocreatine levels
in DMD iPSC-CMs.
Conclusion: In summary, DMD iPSC-CMs exhibit an attenuated β-
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Background: Myopalladin (MYPN) is a 145 kDa striated muscle-
specific sarcomeric protein belonging to the palladin (PALLD)/MYPN/
myotilin family of actin-associated immunoglobulin-containing pro-
teins in the Z-line. MYPN gene mutations are causative for dilated
(DCM), hypertrophic and restrictive cardiomyopathy.
Methods and results: To determine whether MYPN expression is
altered during disease, we performed qRT-PCR on cardiac biopsies
from DCM (n=8) and ischemic cardiomyopathy (ICM) (n=8)
patients vs. healthy subjects (n=5). This revealed a 2.7 fold
upregulation of MYPN mRNA in DCM patients as well as a similar
2.5 fold upregulation of PALLD mRNA, encoding the 200 kDa striated
muscle-specific PALLD isoform, structurally homologous to MYPN. In
contrast, levels of transcripts encoding the ubiquitously expressed
smaller isoforms of PALLD were unaltered. As previously reported
also MYPN’s interaction partner ANKRD1/CARP was 4.5 fold upreg-
ulated in DCM patients.
To determine the functional role of MYPN, we generated MYPN
knockout (MKO) mice, which had a normal life span but were
significantly smaller compared to wildtype (WT) controls. Cardiac
analyses of MKO mice showed the development of progressive cardiac
dilation and decreased fractional shortening starting from 4 months of
age, which was associated decreased tension generation and increased
resting tension in ventricularmyofibrils. Following transaortic constric-
tion, MKO mice exhibited a normal hypertrophic response, but
developed severe cardiac dilation and systolic dysfunction, associated
with upregulation of CARP protein and reduced CSQ2 protein and Akt-
473 phosphorylation levels.
Conclusion: Furthermore, analyses on isolated adult cardiomyocytes
showed reduced sarcomere contractility, and calcium spark fre-
quency and amplitude in MKO mice compared to WT, consistent
with altered calcium signaling.
Funding: Italian Space Agency (ASI), Telethon Foundation Italy.
doi:10.1016/j.yjmcc.2018.05.129
Poster session 4
Name of presenter: Larissa M. Dorsch
Abstract # 116
Cardiomyopathy-related Tropomyosin mutations impair calcium
handling: the influence of mutation location
L.M. Dorsch, P.A. van der Zwaag, L.G. Boven, K.Y. vanSpaendonck-Zwarts,
D.W.D. Kuster, J. van der Velden, J.D.H. Jongbloed, B.J.J.M. Brundel
Physiology, VU University Medical Center
Background: Mutations within the α-Tropomyosin gene (TPM1)
can cause dominantly inherited cardiomyopathies (CM), including
dilated (DCM), hypertrophic (HCM), and restrictive CM (RCM). How
mutations in the same gene lead to such variability in clinical
manifestation is largely unknown. Our aim is to study the functional
consequence of different TPM1 mutations in more detail.
Methods and results: Wildtype and mutant forms of TPM1 (E62Q
(HCM, RCM), T201M (DCM), M281T (HCM), and double mutant E62Q-
M281T (RCM)) were overexpressed in HL-1 cardiomyocytes. Calcium
transients (CaT) were measured 48h and 72h after double transfection
of TPM1 and red fluorescent protein (RFP). Compared to wildtype,
overexpression of mutant TPM1 for 48h significantly reduced CaT
amplitudes to different levels dependent on the mutation, with T201M
and M281T having the strongest effect. The reduction was enhanced
after 72h overexpression. No significant differences in relaxation
parameters were observed between wildtype and mutant TPM1
forms. Using different ratios of RFP and V5-tagged T201M, we were
able to express T201M in a dose-dependent manner, which enables
future studies on the effect of mutant doses.
Conclusion: This study shows that location of mutations in TPM1 gene
determines the degree of calcium handling dysfunction. Overexpression
of mutant TPM1 leads to time-dependent progressive deterioration of
calcium transients. In ongoing experiments, we will determine if calcium
handling dysfunction is influenced by the dose of mutant protein. These
results may explain the variable clinical outcomes in patients carrying
different mutations within TPM1 gene.
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